*Target Lesion Failure (TLF) defined as a composite of Cardiac Death, Target-Vessel Myocardial Infarction (TV-MI), emergent Coronary Artery Bypass Grafting (eCABG) and Clinically-Driven Target Lesion Revascularization (Clinically-driven TLR). FUP= Follow-up; All events have been adjudicated by an independent clinical event committee. BIOSOLVE-II and -IV based on Kaplan-Meier failure estimate analysis including censored observations. The pooled analysis of BIOSOLVE-II and -III based on frequency analysis. The 36-month data of BIOSOLVE-II and -III analysis reflecting a period up to 1’125 days at 3 years. Please consult IFU for indications and use in special populations.
Magmaris is a trademark or registered trademark of the BIOTRONIK Group of Companies.
Magmaris is currently not available in the US.
© 2022 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.